No effect of aspirin on mammographic density in a randomized controlled clinical trial

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 5, 2009, Pages 1524-1530

  McTiernan, Anne ^a,b   Wang, C Y ^a   Sorensen, Bess ^a   Xiao, Liren ^a   Buist, Diana S M ^c   Aiello Bowles, Erin J ^c   White, Emily ^a,b   Rossing, Mary Anne ^a,b   Potter, John ^a,b   Urban, Nicole ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEADACHE; HEMATEMESIS; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN BRUISING; THORAX PAIN; TREATMENT DURATION; VAGINA BLEEDING;

AGED; ASPIRIN; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LINEAR MODELS; MAMMOGRAPHY; MIDDLE AGED; POSTMENOPAUSE; RISK FACTORS;

EID: 66549084850     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-1088     Document Type: Article

References (41)

1. Abou-Issa H, Alshafie G, Harris R, Chemoprevention of breast cancer by nonsteroidal anti-inflammatory drugs and selective COX-2 blockade in animals., COX-2 Blockade in Cancer Prevention and Therapy. Totowa (NJ): Humana Press; 2002. p. 95-98
2. Alshafie G, Harris R, Robertson F, Parrett M, Ross M, Abou-Issa H. Comparative chemopreventive activity of ibuprofen and N-(4-hydroxyphenyl) retinamide against the development and growth of rat mammary adenocarcinomas. Anticancer Res 1999;19:3031-3036 (Pubitemid 30042586)
3. Joarder F, Abou-Issa H, Robertson F, Parrett M, Alshafie G, Harris R. Growth arrest of DMBA-induced mammary carcinogenesis with ibuprofen treatment in Sprague-Dawley rats. Oncol Rep 1997;4:1271-1273 (Pubitemid 27441622)
4. Lee I-M, Sesso HD, Paffenbarger RS. Physical activity and risk of lung cancer. Int J Epidemiol 1999;28:620-625 (Pubitemid 29401318)
5. Steele V, Moon R, Lubet R. Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI Chemoprevention Drug Development Program. J Cell Biochem Suppl 1994;20:32-54.
6. Takkouche B, Regueira-Mendez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 2008;100:1439-1447
7. Zhang SM, Cook NR, Manson JE, Lee IM, Buring JE. Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. Br J Cancer 2008;98:989-991
8. Taketo M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part 1). J Natl Cancer Inst 1998;90:1529-1536 (Pubitemid 28535717)
9. Brueggemeier R, Quinn A, Parrett M, Joarder F, Harris R, Robertson F. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 1999;140:27-35. (Pubitemid 29251310)
10. Hudson AG, Gierach GL, Modugno F, et al. Nonsteroidal antiinflammatory drug use and serum total estradiol in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008;17:680-687
11. Harris R, Namboodiri K, Farrar W. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 1996;7:203-205 (Pubitemid 26068056)
12. Barlow WE, White E, Ballard-Barbash R, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 2006;98:1204-1214 (Pubitemid 44390991)
13. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7:1133-1144 (Pubitemid 29001671)
14. Byrne C, Schairer C, Brinton LA, et al. Effects of mammographic density and benign breast disease on breast cancer risk (United States). Cancer Causes Control 2001;12:103-110 (Pubitemid 32165267)
15. Byrne C, Schairer C, Wolfe J, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 1995;87:1622-1629
16. Chen J, Pee D, Ayyagari R, et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 2006;98:1215-1226 (Pubitemid 44390992)
17. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 2008;148:337-347
18. Ursin G, Ma H, Wu AH, et al. Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev 2003;12:332-338 (Pubitemid 36427994)
19. Ziv E, Tice J, Smith-Bindman R, Shepherd J, Cummings S, Kerlikowske K. Mammographic density and estrogen receptor status of breast cancer. Cancer Epidemiol Biomarkers Prev 2004;13:2090-2095 (Pubitemid 40054303)
20. McTiernan A, Martin CF, Peck JD, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: women's health initiative randomized trial. J Natl Cancer Inst 2005;97:1366-1376 (Pubitemid 41487804)
21. Brisson J, Brisson B, Cote G, Maunsell E, Berube S, Robert J. Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 2000;9:911-915
22. Chow CK, Venzon D, Jones EC, Premkumar A, O'Shaughnessy J, Zujewski J. Effect of tamoxifen on mammographic density. Cancer Epidemiol Biomarkers Prev 2000;9:917-921
23. Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 2004;96:621-628 (Pubitemid 38584986)
24. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-1662 (Pubitemid 41672231)
25. Maskarinec G, Urano Y, Gill J, Kolonel LN. Nonsteroidal antiinflammatory drugs (NSAIDs) and mammographic density. Breast Cancer Res Treat 2008;112:133-139
26. Terry MB, Buist DS, Trentham-Dietz A, James-Todd TM, Liao Y. Nonsteroidal anti-inflammatory drugs and change in mammographic density: a cohort study using pharmacy records on over 29,000 postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008;17:1088-1095
27. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007;356:227-236 (Pubitemid 46143226)
28. American College of Radiology. Breast Imaging - Reporting and Data System (BI-RADS). Reston VA; 1998.
29. Baron J, Cole B, Sandler R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-899 (Pubitemid 36297997)
30. Sandler R, Halabi S, Baron J, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer [comment][erratum appears in N Engl J Med. 2003 May 8;348(19):1939]. N Engl J Med 2003;348:883-890
31. Boyd D, Florent G, Chakrabarty S, Brattain D, Brattain MG. Alterations of the biological characteristics of a colon carcinoma cell line by colon-derived substrata material. Cancer Res 1988;48:2825-2831 (Pubitemid 18137759)
32. Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995;87:670-675
33. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-890 (Pubitemid 36297996)
34. Vogel VG, Costantino JP, Wickerham DL, et al. National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41. Epub 2006 Jun 5. Erratum in: JAMA 2006;296:2926.
35. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300. (Pubitemid 36126189)
36. Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD, Panoulis KP, Kelekis DA, Creatsas GC. Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study. Menopause 2002;9:110-116 (Pubitemid 34194105)
37. Cigler T, Fabian CF, Yaffe MJ, et al. Effects of the steroidal aromatase inhibitor exemestane on mammographic breast density and other end-organ functions. SABCS 2007. http://www.abstracts2view.com/sabcs07/lookup-view.php? word=Cigler&where=authors&return=%2Fsabcs07%2Fauthorindex. php%3Fnum%3D2%26page%3D4%26start%3D120%26stop%3D40.
38. Cigler T, Yaffe MJ, Johnston D, et al. A placebo-controlled trial examining the effects of letrozole on mammographic breast density and bone and lipidmetabolism.SABCS 2007. http://www.abstracts2view.com/sabcs07/lookup-view. php?word=Cigler&where=authors&return=%2Fsabcs07%2Fauthorindex. php%3Fnum%3D2%26page%3D4%26start%3D120%26stop%3D40.
39. Freedman M, San Martin J, O'Gorman J, et al. Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst 2001;93:51-56 (Pubitemid 32060890)
40. Harris R, Chlebowski R, Jackson R, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003;63:6096-6101 (Pubitemid 37187516)
41. Yaffe MJ. Mammographic density. Measurement of mammographic density. Breast Cancer Res 2008;10:209.